How effective is Sotorasib?

Sotorasib (Sotorasib) has shown certain efficacy in the treatment of KRAS G12C mutated non-small cell lung cancer (NSCLC). Based on the results of clinical trials, sotoraxib has significant antitumor activity in certain cases of these patients. The effectiveness of sotorasiib may vary based on individual circumstances. Before using sotoraxib to treat non-small cell lung cancer, you should discuss the efficacy, side effects, and appropriate treatment plan with your doctor.

In aPhase II clinical trial, sotoracib showed good tolerability and efficacy in the treatment of NSCLC patients with KRAS G12C mutations. The results of the study showed that sotoracib caused tumor shrinkage in approximately 36% of patients, and approximately 4% of patients experienced complete tumor shrinkage. This is a positive result, especially considering that the KRAS G12C mutation is relatively common in NSCLC and difficult to treat.

SotoracibThe original drug has not yet been launched in China, so it is not covered by medical insurance. Domestic patients cannot yet purchase this drug. The price of Hong Kong original research versionsotorasibuSpecifications120mg*240 tablets is about RMB 80,000, and the European original research version 120mg*240 tablets is priced at about RMB 44,040 (the price may fluctuate due to the exchange rate), which is relatively expensive. There are also cheaper generic drugs for sale in other countries. The specifications of the Laos Element Pharmaceutical Factory are 120mg*56 tablets and the price is around 4800 yuan (the price may fluctuate due to the exchange rate). The price is relatively cheap. The ingredients of foreign generic drugs are basically the same as the original drugs.